Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia.
Eur J Prev Cardiol
; 30(17): 1874-1880, 2023 11 30.
Article
em En
| MEDLINE
| ID: mdl-37314419
This mathematical modelling analysis demonstrated that evinacumab in addition to standard-of-care lipid-lowering treatments (LLTs; high-intensity statin plus ezetimibe plus proprotein convertase subtilisin/kexin type 9 inhibitor) could increase long-term survival to a median of 77 years vs. the 65 years achieved with only standard-of-care LLTs in patients with homozygous familial hypercholesterolaemia.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Hipercolesterolemia Familiar Homozigota
/
Hiperlipoproteinemia Tipo II
/
Anticolesterolemiantes
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article